1.. Introduction {#S0001}
================

Epidemiological studies showed that vitamin D deficiency is associated with increased mortality; however, there was not enough evidence that vitamin D status is inversely associated with cancer mortality \[[1](#CIT0001)\]. The association between cancer risk and vitamin D has been studied in many epidemiologic studies, while data from interventional studies remain insufficient \[[2](#CIT0002)\]. Almost all studies have proven that vitamin D has a strong and beneficial effect antagonizing and blocking multiple mitogenic processes related to tumorigenesis \[[2](#CIT0002)\]. The association between solar ultraviolet-B exposure and cancer was proven, and it was stronger for mortality than for incidence for many cancers in the USA and China \[[3](#CIT0003),[4](#CIT0004)\].

Vitamin D is highly important for bone health and mineral metabolism, and it is quite known that vitamin D deficiency can lead to rickets, osteomalacia and many other diseases \[[5](#CIT0005)\]. In the recent past, however, vitamin D has been studied for the prevention of many highly prevalent cancer types. One of the most important studies was a randomized controlled trial (RCT) in 2003 that provided good evidence of the antineoplastic effect that vitamin D had in the colon, in addition to the role of vitamin D in reducing the recurrence of colorectal adenoma \[[6](#CIT0006)\]. In a recent meta-analysis of observational studies, low 25-hydroxy vitamin D level was directly related to breast cancer, while total vitamin D and supplemental vitamin D intake had an inverse relationship with breast cancer \[[7](#CIT0007)\].

Although The USA Preventive Services Task Force stated in 2014 that data were insufficient to confirm the effectiveness of vitamin D supplementation for cardiovascular disease or cancer prevention \[[8](#CIT0008)\], yet, the role of vitamin D supplementation in primary prevention for cancer is promising \[[9](#CIT0009)\]. With rapidly surfacing large randomized controlled trials (RCTs) studying this subject \[[10](#CIT0010)--[13](#CIT0013)\], we aimed to evaluate the efficacy and safety of vitamin D supplementation as a means of primary prevention of cancer.

2.. Methods {#S0002}
===========

2.1.. Data sources {#S0002-S2001}
------------------

The study was performed using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) Statement 2015 \[[14](#CIT0014)\]. A comprehensive search of literature using PubMed, Embase, and the Cochrane Collaboration Central Register of Controlled Trials from inception to December 2018 was performed by TH, IG and YZ. Any disagreements were resolved via consensus. The search terms and their substitutes used were as follows: vitamin D, primary prevention, mortality, cancer incidence, bleeding and cancer.

PRISMA checklist was completed ([Table 1](#T0001)).10.1080/20009666.2019.1701839-T0001Table 1.PRISMA 2009 checklist.Section/topic\#Checklist itemReported on page \#**TITLE** Title1Identify the report as a systematic review, meta-analysis, or both.1**ABSTRACT** Structured summary2Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.2**INTRODUCTION** Rationale3Describe the rationale for the review in the context of what is already known.3Objectives4Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).3**METHODS** Protocol and registration5Indicate if a review protocol exists, if and where it can be accessed (e.g. Web address), and, if available, provide registration information including registration number.NAEligibility criteria6Specify study characteristics (e.g. PICOS, length of follow-up) and report characteristics (e.g. years considered, language, publication status) used as criteria for eligibility, giving rationale.4Information sources7Describe all information sources (e.g. databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.4Search8Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.4Study selection9State the process for selecting studies (i.e. screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).4Data collection process10Describe method of data extraction from reports (e.g. piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.4Data items11List and define all variables for which data were sought (e.g. PICOS, funding sources) and any assumptions and simplifications made.4Risk of bias in individual studies12Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.5Summary measures13State the principal summary measures (e.g. risk ratio, difference in means).5Synthesis of results14Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g. I^2^) for each meta-analysis.5Risk of bias across studies15Specify any assessment of risk of bias that may affect the cumulative evidence (e.g. publication bias, selective reporting within studies).5Additional analyses16Describe methods of additional analyses (e.g. sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.5**RESULTS** Study selection17Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.[Figure 1](#F0001)Study characteristics18For each study, present characteristics for which data were extracted (e.g. study size, PICOS, follow-up period) and provide the citations.[Tables 2](#T0002) & [3](#T0003)Risk of bias within studies19Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).5,6Results of individual studies20For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.5,6Synthesis of results21Present results of each meta-analysis done, including confidence intervals and measures of consistency.5,6Risk of bias across studies22Present results of any assessment of risk of bias across studies (see Item 15).6Additional analysis23Give results of additional analyses, if done (e.g. sensitivity or subgroup analyses, meta-regression \[see Item 16\]).6**DISCUSSION** Summary of evidence24Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g. healthcare providers, users, and policy makers).7Limitations25Discuss limitations at study and outcome level (e.g. risk of bias), and at review-level (e.g. incomplete retrieval of identified research, reporting bias).7,8Conclusions26Provide a general interpretation of the results in the context of other evidence, and implications for future research.8**FUNDING** Funding27Describe sources of funding for the systematic review and other support (e.g. supply of data); role of funders for the systematic review.NA[^1] 10.1080/20009666.2019.1701839-T0002Table 2.Jadad scoring of included studies.StudiesJadad scoreGallagher 20015Trivedi 20034Lappe 20075Lacroix 20095Sanders 20104Avenell 20124Baron 20154Jorde 20164Lappe 20175Manson 20185 10.1080/20009666.2019.1701839-T0003Table 3.Details of the randomized clinical trials.StudiesCountry/SitesTotal number of patients/Subgroups25- hydroxy vitD level (standard deviation in nmol/liter)Study designFollow-upVit D form and doseDuration of therapyPrimary outcomesSecondary outcomesGallagher 2001USAVit-D: 203\
Placebo: 213\
Total: 416Initial: Vit-D: 79 (25.5)\
Placebo: 78.9 (25.9)Randomized, double blinded, placebo controlled trial3 yearsCalcitriol (0.25ug twice daily),3 yearsBone mineral density of:\
-Femoral neck\
- Spine.Bone mineral density of:\
-Trochanter\
-Total hip\
-Total body\
-RadiusTrivedi 2003UKVit-D: 1,345\
Placebo: 1,341\
Total: 2,686Post treatment levels:\
Vit D: 72.0 (22.5)\
Placebo: 45.37 (17.6)Randomized, double blinded, Placebo controlled trial5 years100,000 IU cholecalciferol every 4 months5 years-Fracture incidence\
--Total mortality by causeNALappe 2007USAVit-D: 446\
Placebo: 733\
Total: 1,179Initial: Vit-D: 71.8 (20)\
Placebo: 71.9 (20.6)\
12 month change:\
Vit D: 96.0 (21.4)\
Placebo: 71 (20.1)Randomized, double blinded, placebo-controlled trial.4 years1100 IU Cholecaliferol every 6 months7 yearsReduction in total mortality.Reduction in total mortality.Lacroix 2009USAVit-D: 18,176\
Placebo: 18,106\
Total: 36,282-Randomized, double blinded, placebo-controlled trial7 years400 IU Cholecaliferol daily4 yearsHip fracture prevention-Other fracture prevention\
-Colorectal cancer preventionSanders 2010AustraliaVit-D: 1,131\
Placebo: 1,125\
Total: 2,256Initial: Vit-D Median (IQR): 53 (40--65)\
Placebo Medium (IQR): 45 (40--57)Randomized, double blinded, placebo controlled trial5 years500,000 IU Cholecalciferol per year3--5 yearsIncidence of falls and fracturesIncidence of fallsAvenell 2012UKVit-D: 2,649\
Placebo: 2,643\
Total: 5,292Initial: accumulative 38 nmol/liter\
Post treatment levels in Vit D group: 62 nmol/liter2X2 factorial, randomized controlled trial3 years800 IU Cholecalciferol per day3 yearsAll cause mortality, vascular disease mortality, cancer mortality and cancer incidence.Mortality from\
-Cardiovascular\
-CerebrovascularBaron 2015USAVit-D: 1,130\
Placebo: 1,129\
Total: 2,259Initial: Vit-D: 59 (22.2)\
Placebo: 60.2 (21.9)Randomized, double-blinded, placebo controlled trial5 years1,000 IU Cholecalciferol per day3 or 5 yearsRecurrent colorectal adenomasNAJorde 2016NorwayVit-D: 256\
Placebo: 255\
Total: 511Initial: Vit-D: 59.9 (21.9)\
Placebo: 61.1 (21.2)\
5-year visit:\
Vit D: 122.3 (25.3)\
Placebo: 66.7 (18.6)Randomized, double blinded, placebo controlled trial5 years20,000 IU Cholecalciferol per week5 yearsProgression to Diabetes Mellitus Type IIChange in\
-Glucose levels,\
-Insulin resistance,\
-Serum lipids,\
-Blood pressure.Lappe 2017USAVit-D: 1,156\
Placebo: 1,147\
Total: 2,303Initial: Vit-D Median (IQR): 82 (80--84)\
Placebo Medium (IQR): 82 (80--85)\
Post treatment:\
Vit-D Median (IQR): 108 (107--111)\
Placebo Medium (IQR): 79 (77--80)Randomized double blinded, placebo-controlled trial4 years2,000 IU Cholecalciferol per week4 yearsIncidence of all-type cancerHypertension, cardiovascular disease, osteoarthritis, colonic adenomas and diabetes, upper respiratory tract infections, and falls.Manson 2018USAVit-D: 12,927\
Placebo: 12,944\
Total: 25,871Initial: Accumulated: 77 (24.1)\
1-year visit:\
Vit D: 104 (25.3)\
Placebo: 75.3 (23.8)2X2 factorial, randomized placebo controlled trial5.3 years2,000 IU Cholecalciferol per day5.3 yearsInvasive cancer of any type and major cardiovascular eventsIncluded site-specific cancers, death from cancer, and additional cardiovascular events[^2] 10.1080/20009666.2019.1701839-F0001Figure 1.The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.

2.2.. Selection criteria and data extraction {#S0002-S2002}
--------------------------------------------

The study inclusion criteria were as follows: (1) All studies are RCTs; (2) Vitamin D is used for primary prevention; (3) Vitamin D is compared to placebo; (4) Cancer mortality or cancer incidence is reported; (5) The vitamin D supplementation is for at least a period of 3 years for all patients. From each eligible study, two authors, TH and IG, extracted the data and a third author, HD, resolved any discrepancies.

2.3.. Outcomes {#S0002-S2003}
--------------

Our primary outcomes were cancer-related mortality and cancer incidence.

2.4.. Quality assessment {#S0002-S2004}
------------------------

The quality of the included studies was assessed independently by two authors, TH and VS, based on the Jadad scoring system ([Table 2](#T0002)).

2.5.. Statistical analysis {#S0002-S2005}
--------------------------

We calculated summary risk ratios (RRs) and 95% confidence intervals (CIs) using the Mantel--Haenszel method for dichotomous data. We used a random-effects model to account for the between-study heterogeneity. Heterogeneity was measured by the Cochran's Q statistic and I^2^ statistic test. Publication bias was assessed by visual inspection of the funnel plot. Furthermore, we explained any heterogeneity (≥20%) by performing sensitivity and meta-regression analyses. Sensitivity analyses were performed by removing trials sequentially and by removing small trials with a patient population less than 1000 patients, or based on follow-up period (\< or \> 5 years). We performed meta-regression analysis based on age, body mass index (BMI), therapy duration, follow-up duration, initial vitamin D level, and vitamin D dose. Analysis was performed using RevMan v5.3 Windows and Comprehensive Meta-Analysis software v3.

3.. Results {#S0003}
===========

3.1.. Study selection and trial characteristics {#S0003-S2001}
-----------------------------------------------

[Figure 1](#F0001) illustrates the study selection process. We included 10 RCTs \[[10](#CIT0010),[11](#CIT0011),[12](#CIT0012),[13](#CIT0013);[15](#CIT0015),[16](#CIT0016),[17](#CIT0017),[18](#CIT0018),[19](#CIT0019),[20](#CIT0020)\] with 79,055 total patients, mean age of 68.07 years, a female percentage of 78.02% and a minimum follow-up of 3 years. [Tables 3](#T0003) and [4](#T0004) illustrate the characteristics of the included trials and patient demographics, respectively.10.1080/20009666.2019.1701839-T0004Table 4.Patient demographics.StudiesAge (years)Sex (female pts)Race (no. of pts)Hormonal use (no. of pts)BMISmoking Hx (no. of pts)HTN (no. of pts)DM\
(no. of pts)Cardiac disease (no. of pts)Cancer Hx (no of pts)Alcohol use (no. of pts)Gallagher 2001Vit-D: 71.5(3.5)\
Placebo: 71.5(4)Vit-D: 203\
Placebo: 213Total: White 480\
Black 6\
Asian 2Vit-D: 102\
Placebo: 101Vit-D: 27.1(4.1)\
Placebo: 27.2(3.9)\-\-\-\-\--Trivedi 2003Vit-D: 73.7 (4.5)\
Placebo: 73.6 (4.6)Vit-D: 326\
Placebo: 323-Vit-D: 21\
Placebo: 21Vit-D: 24.4 (3.8)\
Placebo: 24.3 (3.8)Vit-D: 20\
Placebo: 24\--Vit-D: 65\
Placebo: 55Vit-D: 15\
Placebo: 10Vit-D: 268\
Placebo: 260Lappe 2007Total: 66.7(7.3)Vit-D: 446\
Placebo: 733Total: White 100%Total: 543Total: 29 (5.7)\-\-\--Vit-D: 0\
Placebo: 0-Lacroix 2009Vit-D: 62.4 (7.0)\
Placebo: 62.4 (6.9)Vit-D: 18,176\
Placebo: 18,106Vit-D: White 15,047\
Non-white 3,129\
Placebo: White 15,106\
Non-white 3,000Vit-D: Past user 3,004\
Current user 9,358\
Placebo: Past user 2,932\
Current user 9,484Vit-D: 29.1 (5.9)\
Placebo: 29.0 (5.9)Vit-D: Past smoker 7,133\
Current 1,356\
Placebo:\
Past smoker 7,255\
Current 1,405Vit-D: 11,232\
Placebo: 11,181Vit-D: 885\
Placebo: 875Vit-D: 1,173\
Placebo: 1,221Vit-D: 0\
Placebo: 0Vit-D: Past drinker 3,192\
Current 12,985\
Placebo:\
Past drinker 3,209\
Current 12,884Sanders 2010Vit-D: 76\
Placebo: 76.1Vit-D: 1,131\
Placebo: 1,125\-\-\-\-\-\-\-\--Avenell 2012Vit-D: 77(6)\
Placebo: 77(6)Vit-D: 2,240\
Placebo: 2,241Vit-D: White 99%\
Placebo:\
White 99%\--Vit-D: 298\
Placebo: 320-Vit-D: 208\
Placebo: 212\-\--Baron 2015Vit-D: 58(6.8)\
Placebo: 57.8(6.6)Vit-D: 418\
Placebo: 418Vit-D:\
White- 951\
Black-96\
Asian 25\
Other- 7\
Placebo: White- 949\
Black-88\
Asian 28\
Other- 16-Vit-D: 28.9(5.5)\
Placebo: 29.1(5.3)Vit-D:\
Former: 421\
Current: 119\
Placebo: Former: 429\
Current Smoker: 96\-\--Vit-D: 0\
Placebo: 0-Jorde 2016Vit-D: 62.3 (8.1)\
Placebo: 61.9 (9.2)Vit-D: 95\
Placebo: 102\--Vit-D: 30.1(4.1)\
Placebo: 29.8(4.4)Vit-D: 59\
Placebo: 47Vit-D: 121\
Placebo: 119100% pre-diabeticVit-D: 0\
Placebo: 0Vit-D: 0\
Placebo: 0-Lappe 2017Vit-D: 65.2 (6.9)\
Placebo: 65.2 (7.1)Vit-D: 1,156\
Placebo: 1,147Vit-D: White 99.4%\
Placebo: White 99.6%Vit-D: 186\
Placebo: 168Vit-D: 29.9(6.6)\
Placebo: 30.2(6.5)Vit-D: 75\
Placebo: 66\-\--Vit-D: 0\
Placebo: 0-Manson 2018Vit-D: 67.1(7)\
Placebo: 67.1(7.1)Vit-D: 6547\
Placebo: 6538Vit-D: White 9,013\
Black 2,553\
Other 1,081\
Placebo:\
White 9,033\
Black 2,553\
Other 1,071-Vit-D: 28.1 (5.7)\
Placebo: 28.1 (5.8)Vit-D: 921\
Placebo: 915Vit-D: 6352\
Placebo: 6439Vit-D: 1,812\
Placebo: 1,737Vit-D: 0\
Placebo: 0Vit-D: 0\
Placebo:0-[^3]

In the 10 included studies, 5 studies explored the role of vitamin D to decrease fracture risk and increase bone health, 3 assessed vitamin D for primary prevention of cancer, 1 study assessed vitamin D's role in colorectal adenoma and 1 study assessed aspirin for use in prevention of diabetes mellitus progression. All studies were randomized controlled trials. Almost all studies were assessed to be of moderate to high quality ([Table 2](#T0002)). Nine of the 10 studies used cholecalciferol as the mean for vitamin D replacement, whereas 1 study used calcitriol; the doses and frequency of supplementation varied from 400 international units (IU) daily to 2000 IU, with reported regimens either daily, weekly, monthly or yearly. Follow-up duration ranged from 3 years to 7 years, while duration of therapy varied from 3 to 6 years. All studies compared vitamin D to placebo.

3.2.. Primary outcome {#S0003-S2002}
---------------------

Vitamin D was associated with significant reduction of cancer-related mortality compared with placebo (RR 0.87; 95% CI: 0.79--0.96; P = 0.05: I^2^ = 0%). Compared with placebo, vitamin D was not associated with significant reduction of cancer incidence (RR: 0.96; 95% CI: 0.86--1.07; P = 0.46; I^2^ = 31%) ([Figure 2](#F0002)). Examination of the funnel plot did not suggest any publication bias ([Figure 3](#F0003)). Sensitivity analysis by removing each trial sequentially demonstrated consistent results.10.1080/20009666.2019.1701839-F0002Figure 2.Forest plot of primary outcome (cancer-related mortality and cancer incidence).10.1080/20009666.2019.1701839-F0003Figure 3.Funnel plot for primary outcome (cancer-related mortality).

A subgroup analysis including the three RCTs that included cancer as a primary outcome only was also conducted where vitamin D was associated with significant reduction of cancer-related mortality when compared to placebo (RR 0.84; 95% CI: 0.72--0.97; P = 0.02: I^2^ = 0%). However, when compared with placebo, vitamin D in this subgroup of RCTs was not associated with significant reduction of cancer incidence (RR: 0.96; 95% CI: 0.84--1.09; P = 0.54; I^2^ = 51%) ([Figure 4](#F0004)).10.1080/20009666.2019.1701839-F0004Figure 4.Forest plot for subgroup analysis (cancer-related mortality and cancer incidence).

For cancer incidence, meta-regression analysis based on age (R^2^ = 46%; *b* = 0.01; *SE* \< 0.01; P = 0.09), BMI (R^2^ = 28%; *b* = −0.06; *SE*= 0.04;P = 0.12), therapy duration (R^2^ = 0%; *b* = 0.01; *SE* = 0.06; P = 0.81), follow-up duration (R^2^ = 0%; *b* \<-0.01; *SE* = 0.07; P = 0.91), initial vitamin D level (R^2^ = 0%; *b \<* -0.01; *SE* \< 0.01; P = 0.47), and vitamin D dose (R^2^ = 0%; *b* \< -0.01; *SE* \< 0.01; P = 0.51) did not significantly explain the heterogeneity.

4.. Discussion {#S0004}
==============

In this meta-analysis of 10 RCTs, vitamin D supplementation was compared to placebo. With the use of vitamin D supplementation for at least 3 years, it was found to have benefit in reducing cancer-related mortality, however, it had no effect on cancer incidence. And when conducting a subgroup analysis including the three RCTs where cancer was reported as a primary outcome, the results were also consistent with the initial analysis results.

Several retrospective studies, large RCTs and meta-analyses have evaluated the role of vitamin D in cancer primary prevention. According to the last review that studied the role of vitamin D in primary prevention of cancer, it was proven that vitamin D supplementation alone as primary prevention had no effect on cancer mortality and incidence. And that was after including 30 RCTs that reported cancer in their outcomes and despite including those that had long-term follow-up \[[21](#CIT0021)\].

Keum et al., in their 2014 review, which included four RCTs with a minimum of 5 years of vitamin D supplementation, proved that long-term vitamin D supplementation did have a benefit in cancer prevention, however, only limited to cancer-related mortality \[[22](#CIT0022)\].

In 2014, a Cochrane review also concluded that there could be decreases in all-cause mortality and cancer-related mortality among vitamin D--treated people in comparison with those who never received it. However, these results could be due to random errors \[[23](#CIT0023)\].

Keum et al. recently reanalyzed their initial meta-analysis by adding newer RCTs with longer follow-up, which proved that vitamin D supplementation significantly reduced total cancer mortality but did not reduce total cancer incidence \[[24](#CIT0024)\].

The strengths of our meta-analysis include an extensive search of the available literature. Furthermore, we included only RCTs, which helps eliminate the likelihood of confounding bias from nonrandomized studies. However, there are several limitations in the included clinical trials. First, over half of the included trials were not primarily studying vitamin D with the intent of preventing cancer and rather all the results were obtained by examining other reported primary outcomes. Second, due to various trial designs and protocols, there were major differences in the vitamin D forms and dosing. Third, only a few clinical trials reported all the predetermined outcomes of our study, and some trials reported only one of the two outcomes either directly or indirectly. Fourth, the follow-up period was short in some of the trials. Fifth, not all trials reported the end of trial 25-hydroxy vitamin D level to examine if the blood vitamin D levels had any effect on cancer mortality or incidence.

5.. Conclusion {#S0005}
==============

With inclusion of studies, which did not primarily examine vitamin D for the purpose of preventing cancer or reducing cancer mortality our meta-analysis highlights that the use of vitamin D supplementation for primary prevention of cancer is encouraged as it does possibly decrease cancer-related mortality once cancer is diagnosed; however, it has no role or effect on cancer incidence. However, this also opens questions for the future with the need for clinical trials that can account for all the limitations of our study including vitamin D form and dosing, length of therapy and exact therapeutic vitamin D levels, to provide stronger evidence and recommendations for the future.
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